Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24785386 | 0.88 | SMN1; SMN2 (0.51) | PSMB5SMN1; SMN2HSD17B10HRH3POLB | |
| SCHEMBL18924053 | 0.87 | PSMB5 (0.38) | PSMB5SMN1; SMN2HSD17B10HRH3TRPA1 | |
| SCHEMBL21319666 | 0.87 | SMN1; SMN2 (0.50) | PSMB5SMN1; SMN2HSD17B10POLBALDH1A1 | |
| SCHEMBL25030508 | 0.80 | TLR2 (0.41) | PSMB5SMN1; SMN2HSD17B10POLBTRPA1 | |
| SCHEMBL25030100 | 0.80 | TLR2 (0.41) | PSMB5SMN1; SMN2HSD17B10POLBTRPA1 | |
| SCHEMBL22987466 | 0.78 | PSMB5 (0.44) | PSMB5SMN1; SMN2HSD17B10POLBALDH1A1 | |
| SCHEMBL14654910 | 0.73 | SMN1; SMN2 (0.55) | SMN1; SMN2HSD17B10POLBTRPA1ALDH1A1 | |
| SCHEMBL15200319 | 0.73 | SMN1; SMN2 (0.55) | SMN1; SMN2HSD17B10POLBTRPA1ALDH1A1 | |
| SCHEMBL17133510 | 0.73 | SMN1; SMN2 (0.55) | SMN1; SMN2HSD17B10POLBTRPA1ALDH1A1 | |
| SCHEMBL21320375 | 0.72 | RECQL (0.39) | HRH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | PSMB5 1114/4885SMN1; SMN2 2324/4885HSD17B10 1340/4885 |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | PSMB5 1114/4885SMN1; SMN2 2324/4885HSD17B10 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.